Skip to main
PRQR
PRQR logo

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics NV is positioned favorably due to the potential acceleration of its pipeline products into clinical trials, which could enhance stock appreciation by yielding proof of concept data sooner than previously anticipated. The company’s Axiomer RNA base-editing platform is viewed as a promising asset, with upcoming clinical data from its first-in-human study expected to significantly impact its valuation. Additionally, ProQR's strong cash position is projected to sustain its operational needs through mid-2027, providing a solid foundation for ongoing research and development efforts.

Bears say

ProQR Therapeutics reported a significant increase in net loss for the quarter, reaching -€12.2 million with a corresponding EPS of (€0.12), a stark contrast to the previous year's loss of -€2.7 million and EPS of (€0.03). This widening loss may raise concerns regarding the company's financial health and operational efficiency. Additionally, the potential for competitive therapeutic options to emerge, combined with reliance on the outcomes of uncertain Phase Ib/II/III studies, contributes to a negative outlook on the stock as future profitability remains uncertain.

ProQR Therapeutics (PRQR) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Buy based on their latest research and market trends.

According to 7 analysts, ProQR Therapeutics (PRQR) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.